Syncona Ltd, a healthcare company focused on founding, building and funding global leaders in life sciences, has appointd Danny Bar-Zohar as a partner.
In this role, Danny will his expertise in clinical development, regulatory environments and medical affairs to help Syncona further build and establish its portfolio of life science companies.
Danny has almost 15 years of experience in the pharmaceutical and biotechnology sector, having worked at Teva Pharmaceutical Industries and Novartis Pharma after practicing medicine for over a decade. He joins from Novartis where, most recently, he was Global Head of Clinical Development and Analytics, leading all late-stage clinical development across neuroscience, immunology, oncology and ophthalmology, amongst others. During his 7 years at Novartis, Danny held multiple roles including Global Head of Neuroscience Development and Chief Scientific Officer of Novartis Pharma Italy.
Before joining Novartis, Danny spent 7 years at Teva Pharmaceutical industries Global Innovative Products division where he headed multiple therapy areas and clinical programmes in Neurology. Prior to Teva, Danny had practiced general surgery at Tel-Aviv Sourasky Medical Center, having studied medicine at the Sackler Faculty of Medicine, Tel-Aviv University in Israel.
Martin Murphy, Chief Executive of Syncona Investment Management Limited, said: “Danny has a wealth of experience in clinical development and we are excited to welcome him to our team. Having served as a surgeon for over a decade, Danny is acutely aware of medicine’s profound impact and we share his drive to improve patient outcomes through transformative treatments. Furthermore, we were particularly drawn to Danny’s deep understanding of the evidence needed to bring high-value therapeutics to patients as this aligns with Syncona’s commercially-oriented found, build, fund strategy.”